RRMS. Diagnose 2023. Erstlinientherapie mit Kesimpta (“Hit hard and early”).

https://www.neurologylive.com/view/role-high-efficacy-therapies-ms-treatment-patricia-k-coyle

"I think you also need to educate the individual with MS, and there is accumulating data suggesting that the best ‘bang for the buck’ in using a high-efficacy agent is to use it early as the initial therapy in treatment-naive individuals. That approach seems to have the greatest impact on avoiding the development of disability years later.” - Patricia K. Coyle, MD (2025 ACTRIMS Forum)